Christer Nordstedt M.D. Ph.D. has over 25 years of experience in various executive positions in the international pharmaceutical industry.

Christer Nordstedt has abroad and extensive international experience within the pharmaceutical industry from operational and strategic positions at management level in companies like Vivesto, Teva Pharmaceuticals, Orion Corporation, Eli Lilly, Roche, AstraZeneca among others. During his career, Christer has been responsible for large global research projects and leadership in both management, executive, and board roles.

Christer’s latest position was interim Chief Executive Officer (CEO) for Vivesto, a pharmaceutical manufacturing company, Uppsala, Sweden. Christer holds a MD and PhD degrees in Pharmacology and Biochemistry from Karolinska Institutet, Sweden. His insights include discovery and clinical development work in neurodegeneration, pain, oncology, and psychiatry.

Dr. Olof Larsson is a pharmacologist with core expertise in pain, neuroscience, and in particular ion channels with excess of 30 years of experience from executive positions in several international big pharma, biotech and start-ups. These include CSO in Pain & Migraine at Eli Lilly, and Scientific site leader Neuroscience, Eli Lilly, US. He has over 90 publications, including several in top-tier journals including Nature and Science. Olof received his PhD at the Karolinska Institute and is an associate professor in Experimental Medicine at the same university.

Dr. Scherlund has extensive experience from the life science industry, from early development to product launch, working at both large and small size companies such as Astra Zeneca, RISE, APL, Moberg Pharma and Cadila Pharmaceuticals. Scherlund holds a Ph.D in Pharmaceutics from Uppsala University, and has wide-ranging leadership experience from different senior management positions, amongst project leadership, regulatory affairs as well as heading departments of pharmaceutical development and quality control.

Mats Jonasson has more than 30 years of experience working with entrepreneur-driven development companies. He has served as CFO in several organizations, especially in Sweden but also abroad. Mats has also worked as a consultant within accounting, auditing and tax matters. He has been co-founder and co-owner of several companies over the years. Mats has a degree in small business economy from the Gothenburg School of Business, Economics and Law.

Mats Lindskog joins Oblique Therapeutics as CBO- Chief Business Officer in Stockholm Office. In his role, Mats will be responsible for business development initiatives to secure overall company growth and to build and strengthen business relations with current and new partners.
Mats has extensive knowledge and experience in areas that will be pivotal in his role at Oblique: Business development, pharmaceutical sales, and antibody technology.

He holds a Master of Science in biotechnology and a PhD within Antibody-based proteomics, both from the Royal Institute of Technology (KTH) in Stockholm. Following his studies Mats worked at start-up biotech companies within antibody production and protein-protein interaction studies and within pharmaceutical Sales and Marketing, specifically within Oncology.
Mats has since then held various executive positions at pharma companies within Business Unit Leadership, Strategy & Operations, Business Excellence and Commercial Operations.

Cecilia Larsson joins Oblique Therapeutics AB as IRM- Investors Relations Manager. In her role, Cecilia is responsible for identifying and engaging with potential new investors, as well as maintaining strong relationships with our current ones.
Cecilia has robust learning and experience with a diverse professional background, including experience in biotech, finance, and entrepreneurial innovation projects, Cecilia brings a wealth of expertise to her role. She has previously served as a Business Relationship Manager and Intellectual Property Rights (IPR) Chef on past projects, demonstrating her ability to excel in business development contexts.
Cecilia has a Double master’s degree, ESLSCA University, Paris, in the field of Marketing and Management.

Dr. Andersson has a background in medicinal chemistry, synthetic organic chemistry, drug discovery and drug development and is particularly knowledgeable in cardiovascular-gastrointestinal diseases and central nervous system (CNS). He is currently a chemistry consultant and founder of KemiKAN. Prior to this, he has held various executive positions within drug discovery such as acting Head of Medicinal Chemistry at AstraZeneca Mölndal but is also the inventor of the drugs Tesaglitazar (GALIDA) and Clevidipine (CLEVIPREX). Dr. Andersson holds a Ph.D. in Physical Organic Chemistry from the University of Gothenburg, Sweden.

Dr. Gannedahl has a long experience from the medical and pharmaceutical industry within the functions medical affairs, clinical research and business development. Combined with his expertise in oncology, translational medicine as well as the U.S. Food and Drug Administration and the needed requirements of drug development such as Good Laboratory Practice (GLP) certification, gives him an edge in the field. He is a medical doctor from Karolinska Institute, has a Ph.D. in Medicine from Uppsala University and has held positions as Global Head of Science Operations at Novartis, VP of R&D in Medical Affairs at Pronova Biopharma, and Executive Global Medical Affairs Leader at AstraZeneca.